BioArctic (BIOA) investor relations material

Executive summary

• Achieved record financial results in 2025, marking a transformative year with significant revenue and profit growth, driven by strong demand for Leqembi and expansion of the innovation pipeline.

• Leqembi established as a leading Alzheimer's treatment, approved in 53 countries, with expanded indications, new formulations, and significant regulatory progress.

• Broadened pipeline with new candidate drugs in ALS, Parkinson's, Huntington's, and synucleinopathies, advancing to preclinical and clinical development.

• Entered new global partnerships with Eisai, Bristol Myers Squibb, and Novartis, enhancing financial and R&D capabilities.

• Advanced BrainTransporter technology, demonstrating improved brain delivery and attracting strong partner interest.

Financial highlights

• Full-year net revenues surged to SEK 2.0 billion, up from 257.4 million, with recurring revenue of SEK 520 million.

• Q4 net revenues were SEK 184 million, with SEK 127 million in royalties and SEK 51 million from Novartis upfront payments.

• Operating profit for the year was SEK 1,258.8 million, with a strong cash position of SEK 2.2 billion at year-end.

• Board proposed a dividend of SEK 2 per share for 2025.

• Operating margin for Q4 was 18.1%; full-year margin was 63%.

Outlook and guidance

• R&D and operating costs are expected to increase by 50%-70% in 2026 as the project portfolio expands, especially in exidavnemab and new candidate drugs.

• Recurring revenues and milestone payments from Leqembi and new launches are expected to continue funding operations and drive further growth.

• Commercial milestone for Leqembi expected in 2026, likely exceeding previous EUR 10 million milestone.

• The company aims to continue investing in R&D and pursue new strategic partnerships.